<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02357576</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00075458</org_study_id>
    <secondary_id>1R01FD005085-01A1</secondary_id>
    <nct_id>NCT02357576</nct_id>
  </id_info>
  <brief_title>Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD</brief_title>
  <official_title>Phase 3 Study of Standard Lipid Therapy Versus Intravenous Fat Emulsion Minimization for the Prevention of Parenteral Nutrition-Associated Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Primary Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parenteral nutrition-associated cholestasis (PNAC) and liver disease (PNALD) are associated
      with significant morbidity and mortality in neonates and is felt to be exacerbated by
      soybean-based lipid emulsions. Much research is currently being directed at identifying ways
      to reduce this risk. Reduction of the dose of soybean-based lipid given as a component of
      parenteral nutrition is one possible strategy. In this study we will compare standard dosing
      of soybean-based lipid (up to 3/kg/day) with a minimized dose (1 g/kg/day) and evaluate for
      the development of cholestasis and adequate growth between the two groups. Longterm followup
      will include an assessment of neurodevelopmental outcomes at 12 and 24 months of age.

      Funding source - FDA OOPD
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of rise of direct bilirubin as a function of time</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cholestasis</condition>
  <arm_group>
    <arm_group_label>Reduced Lipid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Lipid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid 20% I.V. Fat Emulsion</intervention_name>
    <arm_group_label>Reduced Lipid</arm_group_label>
    <arm_group_label>Standard Lipid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  neonates and infants who are at least 28 weeks corrected gestational age at the time
             of enrollment who are parenteral nutrition (PN) naive

          -  current direct bilirubin &lt;2 mg/dL

          -  any of the following conditions:

          -  meconium ileus and peritonitis

          -  gastroschisis

          -  omphalocele &gt;4cm or with liver herniated outside of the abdominal cavity

          -  necrotizing enterocolitis requiring surgical intervention

          -  volvulus

          -  intestinal atresia with &gt;50% bowel loss

        Exclusion Criteria:

          -  weight &lt;1 kg

          -  metabolic pathway defect which is associated with liver dysfunction in the neonatal
             period, including: hereditary fructose intolerance, galactosemia due to transferase
             deficiency and neonatal tyrosinemia, and/or disorder of lipid metabolism

          -  hepatic insufficiency as documented by either a biopsy with cirrhosis and/or marked
             aberration in synthetic function

          -  renal failure

          -  primary or secondary liver disease, regardless of liver function (includes hepatitis)

          -  use of extracorporeal membrane oxygenation (ECMO)

          -  suspected congenital obstruction of the hepatobiliary tree

          -  documented active infection which may be communicable, including infections hepatitis
             or HIV

          -  previous receipt of choleretic agents

          -  currently receiving phenobarbital or other barbiturates

          -  history of PNAC

          -  direct bilirubin &gt;=2 mg/dL at time of enrollment

          -  congenital or acquired anomaly which will require major cardiovascular surgery

          -  major congenital or chromosomal anomaly

          -  hypoxic ischemic encephalopathy

          -  congenital defect of the brain

          -  major seizure disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meghan A Arnold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meghan A Arnold, MD</last_name>
    <phone>734-936-8978</phone>
    <email>meghanar@med.umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado/Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saleem Islam, MD</last_name>
      <email>saleem.islam@surgery.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Saleem Islam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan A Arnold, MD</last_name>
      <phone>734-936-8978</phone>
      <email>meghanar@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Meghan A Arnold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seth Warschausky, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Javid, MD</last_name>
      <email>patrick.javid@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Patrick Javid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2015</study_first_submitted>
  <study_first_submitted_qc>February 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2015</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Meghan A. Arnold, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

